Chiome Bioscience Inc. 4583.T Stock
Chiome Bioscience Inc. Price Chart
Chiome Bioscience Inc. 4583.T Financial and Trading Overview
Chiome Bioscience Inc. stock price | 131 JPY |
Previous Close | 200 JPY |
Open | 200 JPY |
Bid | 203 JPY x N/A |
Ask | 204 JPY x N/A |
Day's Range | 200 - 204 JPY |
52 Week Range | 135 - 261 JPY |
Volume | 269.5K JPY |
Avg. Volume | 1.21M JPY |
Market Cap | 9.88B JPY |
Beta (5Y Monthly) | 0.930651 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -24.62 JPY |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
4583.T Valuation Measures
Enterprise Value | 8.51B JPY |
Trailing P/E | N/A |
Forward P/E | -6.9387755 |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 14.7076645 |
Price/Book (mrq) | 6.3228364 |
Enterprise Value/Revenue | 12.678 |
Enterprise Value/EBITDA | -8.535 |
Trading Information
Chiome Bioscience Inc. Stock Price History
Beta (5Y Monthly) | 0.930651 |
52-Week Change | 19.76% |
S&P500 52-Week Change | 20.43% |
52 Week High | 261 JPY |
52 Week Low | 135 JPY |
50-Day Moving Average | 208.5 JPY |
200-Day Moving Average | 175.75 JPY |
4583.T Share Statistics
Avg. Volume (3 month) | 1.21M JPY |
Avg. Daily Volume (10-Days) | 643.95K JPY |
Shares Outstanding | 48.42M |
Float | 44.06M |
Short Ratio | N/A |
% Held by Insiders | 6.57% |
% Held by Institutions | 4.02% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor | 2:1 |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | -145.62% |
Operating Margin (ttm) | -148.70% |
Gross Margin | -75.82% |
EBITDA Margin | -148.54% |
Management Effectiveness
Return on Assets (ttm) | N/A |
Return on Equity (ttm) | N/A |
Income Statement
Revenue (ttm) | 671.65M JPY |
Revenue Per Share (ttm) | 14.75 JPY |
Quarterly Revenue Growth (yoy) | N/A |
Gross Profit (ttm) | -786755000 JPY |
EBITDA | -997676032 JPY |
Net Income Avi to Common (ttm) | -978113024 JPY |
Diluted EPS (ttm) | -20.99 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 1.57B JPY |
Total Cash Per Share (mrq) | 32.35 JPY |
Total Debt (mrq) | 301M JPY |
Total Debt/Equity (mrq) | 19.27 JPY |
Current Ratio (mrq) | 4.188 |
Book Value Per Share (mrq) | 32.264 |
Cash Flow Statement
Operating Cash Flow (ttm) | N/A |
Levered Free Cash Flow (ttm) | N/A |
Profile of Chiome Bioscience Inc.
Country | Japan |
State | N/A |
City | Tokyo |
Address | Sumitomo-Fudosan Nishi-shinjuku building |
ZIP | 151-0071 |
Phone | 81 3 6383 3561 |
Website | https://www.chiome.co.jp |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | N/A |
Chiome Bioscience Inc. engages in the research and development of drug discovery technology platforms worldwide. The company operates through two segments, Drug Discovery and Development Business and Drug Discovery Support Business. It offers ADLib System, a monoclonal antibody generating system for drug discovery and development. The company also provides protein expression and purification services; stable cell line generation services for recombinant protein and antibody production; and antibody generation services using the ADLib system or B cell cloning techniques. Its product pipeline includes ADCT-701, an anti-dlk1 antibody for treating liver cancer; CBA-1205, an afucosylated anti-dlk1 antibody for liver cancer, lung cancer, neuroblastoma, etc.; CBA-1535, an anti 5T4/WAIF1 antibody for malignant mesothelioma, small cell lung cancer, non-small cell lung cancer, breast cancer (TNBC), etc.; LIV-2008/2008b, an anti-TROP-2 antibody for the treatment of TNBC, lung cancer, colorectal cancer, etc.; and BMAA, an anti-semphorin3a antibody for treating central, immune/ inflammatory diseases, neurological disorder, and ophthalmic diseases. The company serves universities, research institutions, and pharmaceutical companies. It has a collaborative research agreement with Mologic Ltd. for antibody discovery and development for use in advanced diagnostic tests. Chiome Bioscience Inc. was incorporated in 2005 and is headquartered in Tokyo, Japan.
Q&A For Chiome Bioscience Inc. Stock
What is a current 4583.T stock price?
Chiome Bioscience Inc. 4583.T stock price today per share is 131 JPY.
How to purchase Chiome Bioscience Inc. stock?
You can buy 4583.T shares on the Tokyo exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Chiome Bioscience Inc.?
The stock symbol or ticker of Chiome Bioscience Inc. is 4583.T.
Which industry does the Chiome Bioscience Inc. company belong to?
The Chiome Bioscience Inc. industry is Biotechnology.
How many shares does Chiome Bioscience Inc. have in circulation?
The max supply of Chiome Bioscience Inc. shares is 54.95M.
What is Chiome Bioscience Inc. Price to Earnings Ratio (PE Ratio)?
Chiome Bioscience Inc. PE Ratio is now.
What was Chiome Bioscience Inc. earnings per share over the trailing 12 months (TTM)?
Chiome Bioscience Inc. EPS is -24.62 JPY over the trailing 12 months.
Which sector does the Chiome Bioscience Inc. company belong to?
The Chiome Bioscience Inc. sector is Healthcare.